Video

Ursula Matulonis Explains the Use of PARP Inhibitors for Ovarian Cancer

Author(s):

Ursula Matulonis, M.D.
Conference|SGO Annual Meeting on Women's Cancer

Ursula Matulonis, M.D., professor of Medicine, Harvard Medical School, Medical Director of Gynecologic Oncology, Dana-Farber Cancer Institute, explains the benefits of PARP inhibitors for patients with ovarian cancer.

Ursula Matulonis, M.D., professor of Medicine, Harvard Medical School, Medical Director of Gynecologic Oncology, Dana-Farber Cancer Institute, explains the benefits of PARP inhibitors for patients with ovarian cancer.

PARP inhibitors work by blocking the repair of DNA within cancer cells, which then allows other DNA repair molecules to target the broken DNA strand.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of man with text.
An expert highlights the impact of anemia in myelofibrosis and presented Ojjaara as a possible treatment to reduce transfusions and improve outcomes.
After ovarian cancer surgery, Mary Barbera spent three months in rehab before finally returning home, a milestone that marked her emotional recovery.
Image of two doctors and text.
Imiage of two doctors with text.
Image of two doctors and text.
Image of patient and doctor.
Image of two doctors with text.
image of gerds
Image of 2 doctors and text.
Related Content
Image of clinical trial.
July 7th 2025

New Trials Target Brain, Bladder, Ovarian and Other Cancers

Spencer Feldman
New clinical trials are advancing in hard-to-treat cancers, offering targeted and less toxic options for patients with limited treatment paths.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Image of two doctors with text.
June 20th 2025

Advancements Reshape Treatment for Non-Small Cell Lung Cancer

Ryan Scott
Dr. Prantesh Jain and Dr. Joshua Sabari delved into the numerous advances in NSCLC following 2025 ASCO, highlighting the REZILIENT-1 and NeoADAURA trials.
cancer horizons image for podcast
December 14th 2023

Conference Highlights from the 2023 ASH Annual Meeting

Brielle Benyon Alex Biese
CURE® recently covered the 2023 American Society of Hematology Annual Meeting. In case you missed it, here is some news that came out of the conference that patients should know about.
Image of kidney
June 19th 2025

Why is Clinical Trial Enrollment Important for Those With Kidney Cancer?

Ryan Scott
Dr. Michael Serzan explains the importance of clinical trial enrollment for patients with kidney cancer and highlighted findings from the STELLA-002 trial.
Image of hands.
June 18th 2025

The Person Behind Their Diagnosis: Understanding the Patient

Ryan Scott
Dr. Joshua Sabari and Jackie Herigodt discuss the Imerman Angels organization and the importance of recognizing the person behind their cancer diagnosis.